Merz reveals primary endpoint met in study of xeomin

Merz Aesthetics has announced positive results from a post-market parallel group clinical trial designed to evaluate the efficacy of xeomin for the treatment of moderate to severe glabellar facial lines compared to botox.

Jim Hartman, vice-president and head of US aesthetics for Merz North America, said the firm is pleased that the data from the study further demonstrates the efficacy of the drug.

He added that the firm remains dedicated to providing information to allow physicians to make the best decisions regarding treatments.

Results of the study show that the trial met its primary efficacy and discovered that the most common side effects of the drug are headache infection and facial asymmetry.

Dr Fredric Brandt, co-lead author of the research and one of the world's foremost leaders in injectables, commented: "The results of this clinical trial offer evidence that there are multiple effective options for injectors and patients seeking a neurotoxin for aesthetic use."

He has spent many years developing innovative methods, new injection techniques and novel uses, meaning he has built a reputation as a pioneer within the skincare industry.

In 2011, xeomin was approved by the US Food and Drug Administration for improvement in the appearance of moderate to severe glabellar frown lines with a recommended dosage of 20 units.